Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin

Int J Clin Pharmacol Ther. 1998 Feb;36(2):61-4.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors*
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Child
  • Cyclophosphamide / administration & dosage
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Dactinomycin / administration & dosage
  • Drug Interactions
  • Etoposide / administration & dosage
  • Fever / chemically induced
  • Humans
  • Ifosfamide / administration & dosage
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Neutropenia / chemically induced
  • Patient Admission
  • Retrospective Studies
  • Sarcoma / drug therapy*
  • Sepsis / chemically induced
  • Soft Tissue Neoplasms / drug therapy*
  • Vincristine / administration & dosage

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Immunosuppressive Agents
  • Dactinomycin
  • Vincristine
  • Etoposide
  • Cyclosporine
  • Cyclophosphamide
  • Ifosfamide

Supplementary concepts

  • VAC protocol